Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia

Table 1 Immune status of vaccinees after all live-virus challenges

Level of protection	Animal name	Virological outcome	Interpretation	Immunogens	Challenge viruses (challenge route)	Enrolled in study
Complete	ROb-12	Aviremic	Cryptic infection	HIV-C gp160 and gp145 + SIV Gag overlapping synthetic peptides (OSP)+ HIV Tat OSP+ SIV Nef OSP	Multiple low-doses with SHIV-2873Nip (intrarectal) [14]	unpublished
	RAt-9	Aviremic	Cryptic infection	HIV-C gp160 + SIV Gag-Pol particles + HIV Tat	Single low-dose with SHIV-1157ip (oral) and single high-dose with SHIV-1157ipd3N4 (intrarectal) [15]	[8–10]
	RQe-10	Aviremic	Sterilizing immunity	Listeria monocytogenes expressing SIV gag + Ad5hr encoding SIV gag + HIV-C gp160 + HIV Tat	Multiple low-doses with SHIV-1157ipEL-p (intrarectal) [13]	[11]
	RRi-11	Aviremic	Sterilizing immunity	HIV-C gp160 + SIV Gag-Pol particles + HIV Tat	Multiple low-doses and one high-dose with SHIV-1157ipEL-p (intrarectal) [13]	[12]
	RTr-11	Aviremic	Cryptic infection
Partial	RBr-11	Lower peak viremia	Chronic systemic infection
	RGe-11	Aviremic during low-dose challenges	2 low-level blips (<10⁴ copies/ml)
None	RDo-11	No protection	Chronic systemic infection

ISSN: 1742-4690